Menopause Linked to Significant Lung Function Decline Regardless of HIV Status

Respiratory Health and the Menopausal Transition

As the life expectancy of women living with human immunodeficiency virus (HIV) continues to improve, clinicians are increasingly tasked with managing the complex intersection of chronic viral infection and reproductive aging [1, 2]. Data from the REPRIEVE trial involving 1,449 women with HIV indicate that advanced reproductive age is significantly associated with metabolic dysregulation, including a waist circumference greater than 88 cm (odds ratio 1.38; 95% confidence interval, 1.06 to 1.80) [2]. While clinical attention during the menopausal transition often focuses on cardiovascular risk and metabolic syndrome (a cluster of conditions including hypertension and dyslipidemia) [3, 4], the systemic impact of estrogen depletion may extend to the pulmonary system. Chronic inflammation and immune activation, characterized by the dysregulated synthesis of interleukin 6 (a signaling protein that triggers systemic inflammatory responses), potentially exacerbate physiological declines in organ function [5]. Despite these risks, current HIV management guidelines lack specific protocols for monitoring respiratory health, and several general menopause resources have recently been archived as outdated [1, 6]. To address this gap, researchers recently analyzed how specific menopausal stages correlate with objective measures of lung function, providing data that could help physicians better anticipate respiratory decline in aging female patients.

Cohort Characteristics and Hormonal Assessment

The researchers analyzed data from 1,206 participants enrolled in the Women's Interagency HIV Study, a multicenter cohort designed to investigate the progression of chronic infections in women. This study population was predominantly composed of women with HIV, who represented 71% of the total group. Demographic data indicated that 65% of the participants were Black, and the median age of the cohort was 52 years. Because tobacco use is a primary driver of respiratory pathology, the researchers documented smoking history, finding that 36% of participants reported current smoking while 31% were former smokers. These baseline characteristics provided a high-risk clinical profile for evaluating the intersection of viral status, lifestyle factors, and pulmonary health. To ensure an objective assessment of reproductive aging, the study determined each participant's menopausal phase using anti-Müllerian hormone (a protein produced by small ovarian follicles that serves as a reliable biomarker of ovarian reserve). This biochemical approach allowed for precise categorization rather than relying solely on self-reported menstrual history, which can be unreliable in clinical settings. Based on these hormone levels, the cohort was divided into three distinct groups: 30% of participants were classified as premenopausal or early perimenopausal, 40% were in the late perimenopausal phase, and 30% were postmenopausal. This distribution enabled the researchers to correlate specific hormonal shifts with objective measures of lung function, drawing on a robust dataset of 1,116 spirometry tests and 615 assessments of diffusing capacity for carbon monoxide (a test that measures how well oxygen moves from the lungs into the blood).

Impact of HIV on Pulmonary Diffusion

The researchers evaluated pulmonary health through a comprehensive dataset collected between 2018 and 2019, which included 1,116 spirometry tests and 615 assessments of diffusing capacity for carbon monoxide (DLco). When examining the specific influence of viral status on lung mechanics, the analysis showed that HIV was not associated with a statistically significant reduction in forced expiratory volume in one second (FEV1) or forced vital capacity (FVC). These findings suggest that the presence of the virus itself does not necessarily impair the mechanical ability of the lungs to move air or the total volume of air a patient can exhale after a deep breath, parameters typically used to diagnose obstructive or restrictive lung diseases. In contrast to the spirometry results, the study identified a distinct impact of viral status on the gas exchange surface of the lungs. HIV was significantly associated with lower diffusing capacity for carbon monoxide (p=0.004), a clinical measure of how effectively oxygen transfers from the alveolar air into the pulmonary capillary blood. This discrepancy indicates that while the mechanical bellows function of the lungs remains relatively preserved in women with HIV, the underlying pulmonary microvasculature or alveolar membrane integrity may be compromised. For the practicing clinician, these results highlight that standard spirometry may not fully capture the extent of pulmonary impairment in this population, as the primary deficit appears to be a reduction in diffusion capacity rather than ventilatory defects.

Age-Specific Declines in Lung Volumes

The researchers stratified the study population into two distinct age groups, 41 to 50 years and 51 to 60 years, to determine if the timing of the menopausal transition influenced the severity of pulmonary decline. After adjusting for demographic, clinical, and behavioral factors, the analysis revealed that significant differences in lung function by menopausal phase were observed exclusively in women aged 41 to 50. In contrast, the researchers found no significant differences in lung function by menopausal phase among women in the 51 to 60 age group. This suggests that the impact of hormonal shifts on respiratory volumes may be most pronounced during the earlier window of reproductive aging, rather than in later years when other age-related physiological changes may predominate. Within the 41 to 50 age bracket, the transition into late perimenopause was associated with measurable reductions in both airflow and lung capacity. Compared to women in the premenopausal or early perimenopausal stages, those in late perimenopause showed a -109 mL (95% CI: -201, -16) lower mean forced expiratory volume in one second (FEV1), which measures the amount of air a person can exhale during the first second of a forced breath. Similarly, these women experienced a -125 mL (95% CI: -223, -28) lower mean forced vital capacity (FVC), the total volume of air that can be forcibly exhaled from the lungs after taking the deepest breath possible. These findings indicate that even before the final menstrual period, the physiological changes of the menopausal transition are linked to a quantifiable decrease in pulmonary bellows function. The decline in pulmonary parameters was even more substantial for women in the 41 to 50 age group who had reached postmenopause. When compared to their premenopausal or early perimenopausal peers, postmenopausal women exhibited a -310 mL (95% CI: -525, -96) lower mean FEV1 and a -307 mL (95% CI: -534, -80) lower mean FVC. These data demonstrate that the transition to a postmenopausal state in a woman's fifth decade is linked to a loss of approximately 300 mL in lung volume. For the practicing clinician, these results emphasize that the menopausal transition itself, independent of chronological age or HIV status, serves as a significant factor in the respiratory health of middle-aged women, necessitating closer monitoring of pulmonary function during this period.

Gas Exchange and Clinical Implications

The researchers also evaluated the diffusing capacity for carbon monoxide (DLco), a clinical measure of how effectively oxygen transfers from the alveolar air sacs into the pulmonary capillaries. Among women aged 41 to 50, those in late perimenopause had a -1.40 mL/min/mmHg (95% CI: -2.39, -0.41) lower mean DLco compared to women in the premenopausal or early perimenopausal stages. This reduction suggests that the transition period itself may involve physiological changes that impair gas exchange across the alveolar-capillary membrane. Interestingly, the study found no clear evidence of a difference in DLco in postmenopausal women aged 41 to 50 when compared to the premenopausal or early perimenopausal reference group. This discrepancy between late perimenopause and postmenopause regarding diffusion capacity warrants further investigation to determine if compensatory mechanisms or survivor bias within the cohort influence these specific gas exchange metrics. Ultimately, these findings establish that the menopausal phase is associated with lung function in women with and without HIV, even after accounting for age. While HIV status was independently associated with a lower DLco (p=0.004), the impact of the menopausal transition on respiratory health remained consistent across both HIV-positive and HIV-negative participants. For the practicing clinician, these data indicate that reproductive aging is a distinct risk factor for pulmonary decline that exists alongside traditional risks such as smoking or viral status. Because the study demonstrates that significant reductions in both lung volumes and diffusion capacity occur during the menopausal transition, further research is needed to understand how estrogen depletion alters lung tissue and respiratory mechanics. Monitoring respiratory symptoms and considering baseline spirometry may be increasingly relevant for women in their 40s as they enter the perimenopausal period.

References

1. Scofield D, Moseholm E, Aebi-Popp K, Hachfeld A. Management of menopause in women living with HIV - A comparative guideline review.. Maturitas. 2024. doi:10.1016/j.maturitas.2024.107937

2. Zanni MV, Currier JS, Kantor A, et al. Correlates and Timing of Reproductive Aging Transitions in a Global Cohort of Midlife Women With Human Immunodeficiency Virus: Insights From the REPRIEVE Trial.. The Journal of infectious diseases. 2020. doi:10.1093/infdis/jiaa214

3. Members AF, Reiner Ž, Catapano AL, et al. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European Heart Journal. 2011. doi:10.1093/eurheartj/ehr158

4. Bowo‐Ngandji A, Kenmoe S, Ebogo‐Belobo JT, et al. Prevalence of the metabolic syndrome in African populations: A systematic review and meta-analysis. PLoS ONE. 2023. doi:10.1371/journal.pone.0289155

5. Tanaka T, Narazaki M, Kishimoto T. IL-6 in Inflammation, Immunity, and Disease. Cold Spring Harbor Perspectives in Biology. 2014. doi:10.1101/cshperspect.a016295

6. SOGC Guideline Retirement Notice No. 1.. Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC. 2022. doi:10.1016/j.jogc.2022.06.009